{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:18:28Z","timestamp":1769836708055,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.mcna.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T20:44:59Z","timestamp":1666385099000},"page":"929-947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Testing and Treating Mycobacterium tuberculosis Infection"],"prefix":"10.1016","volume":"106","author":[{"given":"Edgar","family":"Ortiz-Brizuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel A.","family":"Behr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2022.08.001_bib1","series-title":"Global tuberculosis report 2021","author":"World Health","year":"2021"},{"issue":"10","key":"10.1016\/j.mcna.2022.08.001_bib2","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling","volume":"13","author":"Houben","year":"2016","journal-title":"Plos Med"},{"issue":"1943","key":"10.1016\/j.mcna.2022.08.001_bib3","first-page":"20201635","article-title":"Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease","volume":"288","author":"Emery","year":"2021","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.mcna.2022.08.001_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","article-title":"Prospects for tuberculosis elimination","volume":"34","author":"Dye","year":"2013","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.mcna.2022.08.001_bib5","doi-asserted-by":"crossref","first-page":"k2738","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.mcna.2022.08.001_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0041-3879(82)80013-5","volume":"63","author":"Sutherland","year":"1982","journal-title":"Tubercle"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib7","first-page":"414","article-title":"Estimation of serial interval and incubation period of tuberculosis using DNA fingerprinting","volume":"3","author":"ten Asbroek","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib8","first-page":"e000060","article-title":"Declaring a tuberculosis outbreak over with genomic epidemiology","volume":"2","author":"Hatherell","year":"2016","journal-title":"Microb Genom"},{"issue":"12","key":"10.1016\/j.mcna.2022.08.001_bib9","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/infdis\/jiv011","article-title":"Reemergence and amplification of tuberculosis in the Canadian arctic","volume":"211","author":"Lee","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.mcna.2022.08.001_bib10","first-page":"m549","article-title":"Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ (Clinical research ed)"},{"issue":"2","key":"10.1016\/j.mcna.2022.08.001_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1164\/rccm.202011-4239PP","article-title":"Latent Tuberculosis: Two Centuries of Confusion","volume":"204","author":"Behr","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.mcna.2022.08.001_bib12","doi-asserted-by":"crossref","first-page":"103928","DOI":"10.1016\/j.ebiom.2022.103928","article-title":"Mind the gap - Managing tuberculosis across the disease spectrum","volume":"17","author":"Esmail","year":"2022","journal-title":"Ebiomedicine"},{"issue":"12","key":"10.1016\/j.mcna.2022.08.001_bib13","doi-asserted-by":"crossref","first-page":"e1044","DOI":"10.1093\/cid\/ciaa1827","article-title":"It Is Time to Focus on Asymptomatic Tuberculosis","volume":"72","author":"Wong","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib14","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2022.08.001_bib15","first-page":"CD001363","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","volume":"2","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"9944","key":"10.1016\/j.mcna.2022.08.001_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mcna.2022.08.001_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A\u00a0Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa","volume":"373","author":"Group","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"359","key":"10.1016\/j.mcna.2022.08.001_bib18","first-page":"368","article-title":"Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income andmiddle -income countries:a systematic review and meta-analysis","volume":"8","author":"Morrison","year":"2008","journal-title":"Lancel Infect Dis"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1183\/09031936.00070812","article-title":"Contact investigation for tuberculosis: a systematic review and meta-analysis","volume":"41","author":"Fox","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mcna.2022.08.001_bib20","unstructured":"Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection. Geneva: World Health Organization; 2022 (WHO\/UCN\/TB\/2022.1). Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2022.08.001_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Rangaka","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mcna.2022.08.001_bib24","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis","volume":"17","author":"Sh","year":"1969","journal-title":"Adv Tuberc Res"},{"issue":"4","key":"10.1016\/j.mcna.2022.08.001_bib25","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"IUATCo","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"10","key":"10.1016\/j.mcna.2022.08.001_bib26","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"RR-6","key":"10.1016\/j.mcna.2022.08.001_bib27","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.mcna.2022.08.001_bib28","series-title":"Canadian Tuberculosis Standards. Canadian lung association","year":"2013"},{"key":"10.1016\/j.mcna.2022.08.001_bib29","unstructured":"World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization; 2015."},{"issue":"11","key":"10.1016\/j.mcna.2022.08.001_bib30","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection:systematic review of students in theUS and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"No.RR-1","key":"10.1016\/j.mcna.2022.08.001_bib31","first-page":"1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR"},{"key":"10.1016\/j.mcna.2022.08.001_bib32","series-title":"Canadian tuberculosis standards","year":"2022"},{"issue":"9","key":"10.1016\/j.mcna.2022.08.001_bib33","doi-asserted-by":"crossref","first-page":"e1003738","DOI":"10.1371\/journal.pmed.1003738","article-title":"Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis","volume":"18","author":"Yanes-Lane","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2022.08.001_bib35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2022.08.001_bib39","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1128\/AAC.00031-16","article-title":"Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans","volume":"60","author":"Zurlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mcna.2022.08.001_bib41","first-page":"365","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","author":"Sterling","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2022.08.001_bib42","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.mcna.2022.08.001_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for Preventing Tuberculosis in Children and Adolescents","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"10","key":"10.1016\/j.mcna.2022.08.001_bib44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.mcna.2022.08.001_bib45","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"KR","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2022.08.001_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4\u00a0months versus isoniazid for 9\u00a0months","volume":"170","author":"D","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.mcna.2022.08.001_bib47","first-page":"149","article-title":"Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib48","first-page":"379","article-title":"Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults","author":"Menzies","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib49","doi-asserted-by":"crossref","DOI":"10.1086\/427802","article-title":"Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2022.08.001_bib50","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic Review, Meta-Analysis, and Cost-Effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib51","doi-asserted-by":"crossref","first-page":"e033945","DOI":"10.1136\/bmjopen-2019-033945","article-title":"Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial","volume":"10","author":"Fox","year":"2020","journal-title":"BMJ Open"},{"issue":"sup1","key":"10.1016\/j.mcna.2022.08.001_bib52","first-page":"49","article-title":"Chapter 4: Diagnosis of tuberculosis infection","volume":"6","author":"Campbell","year":"2022","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"10.1016\/j.mcna.2022.08.001_bib53","first-page":"1","article-title":"Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli","volume":"19","author":"Sutherland","year":"1976","journal-title":"Adv Tuberc Res"},{"key":"10.1016\/j.mcna.2022.08.001_bib54","series-title":"WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment","author":"World Health","year":"2020"},{"issue":"7","key":"10.1016\/j.mcna.2022.08.001_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6907a1","article-title":"Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association","volume":"69","author":"Cole","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"sup1","key":"10.1016\/j.mcna.2022.08.001_bib56","first-page":"77","article-title":"Chapter 6: Tuberculosis preventive treatment in adults","volume":"6","author":"Alvarez","year":"2022","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"Rr-15","key":"10.1016\/j.mcna.2022.08.001_bib57","first-page":"1","article-title":"Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC","volume":"54","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/ajrccm.159.1.9801120","article-title":"Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion","volume":"159","author":"Menzies","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.mcna.2022.08.001_bib59","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1371\/journal.pmed.0040208","article-title":"Serial testing for tuberculosis: can we make sense of T\u00a0cell assay conversions and reversions?","volume":"4","author":"Pai","year":"2007","journal-title":"Plos Med"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"10.1016\/j.mcna.2022.08.001_bib61","doi-asserted-by":"crossref","first-page":"e1001270","DOI":"10.1371\/journal.pmed.1001270","article-title":"Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis","volume":"9","author":"Suthar","year":"2012","journal-title":"Plos Med"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib62","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2352-3018(20)30299-X","article-title":"Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data","volume":"8","author":"Ross","year":"2021","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.mcna.2022.08.001_bib63","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa","volume":"377","author":"Hakim","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2022.08.001_bib64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5588\/ijtld.21.0049","article-title":"A\u00a0systematic review of the number needed to screen for active TB among people living with HIV","volume":"25","author":"Chaisson","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.mcna.2022.08.001_bib65","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1016\/S2352-3018(18)30137-1","article-title":"Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis","volume":"5","author":"Hamada","year":"2018","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.mcna.2022.08.001_bib66","doi-asserted-by":"crossref","first-page":"e32482","DOI":"10.1371\/journal.pone.0032482","article-title":"Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis","volume":"7","author":"Santin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mcna.2022.08.001_bib67","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12879-016-1687-8","article-title":"Accuracy of the interferon-gamma release assay for the diagnosis of active tuberculosis among HIV-seropositive individuals: a systematic review and meta-analysis","volume":"16","author":"Huo","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.mcna.2022.08.001_bib68","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"02","key":"10.1016\/j.mcna.2022.08.001_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1142\/S2661341721500012","article-title":"Recommendations on Management of Latent Tuberculosis Infection in Patients Initiating Anti-tumor Necrosis Factor Biologics","volume":"21","author":"O\u2019Young","year":"2021","journal-title":"J\u00a0Clin Rheumatol Immunol"},{"issue":"9","key":"10.1016\/j.mcna.2022.08.001_bib71","doi-asserted-by":"crossref","first-page":"e022445","DOI":"10.1136\/bmjopen-2018-022445","article-title":"Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines","volume":"8","author":"Hasan","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.mcna.2022.08.001_bib72","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1086\/597590","article-title":"Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology","volume":"48","author":"Aguado","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.01.034","article-title":"Tuberculosis and chronic kidney disease: an emerging global syndemic","volume":"90","author":"Romanowski","year":"2016","journal-title":"Kidney Int"},{"issue":"37","key":"10.1016\/j.mcna.2022.08.001_bib74","first-page":"873","article-title":"Tuberculosis transmission in a renal dialysis center--Nevada, 2003","volume":"53","author":"Centers for Disease C Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.mcna.2022.08.001_bib75","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mcna.2022.08.001_bib76","doi-asserted-by":"crossref","first-page":"100218","DOI":"10.1016\/j.jctube.2021.100218","article-title":"Mini-review: Silico-tuberculosis","volume":"23","author":"Lanzafame","year":"2021","journal-title":"J\u00a0Clin Tuberc Other Mycobact Dis"},{"issue":"9830","key":"10.1016\/j.mcna.2022.08.001_bib77","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(12)60235-9","volume":"379","author":"Leung","year":"2012","journal-title":"Silicosis Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib78","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1186\/s12889-021-10711-1","article-title":"The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis","volume":"21","author":"Ehrlich","year":"2021","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.mcna.2022.08.001_bib79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/thx.2010.139048","article-title":"Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial","volume":"66","author":"Churchyard","year":"2011","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib80","first-page":"474","article-title":"Silica, silicosis and tuberculosis","volume":"11","author":"Rees","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A\u00a0double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"10.1016\/j.mcna.2022.08.001_bib82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa1214289","article-title":"A\u00a0trial of mass isoniazid preventive therapy for tuberculosis control","volume":"370","author":"Churchyard","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib83","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.201409-1704OC","article-title":"The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents","volume":"191","author":"Andrews","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.mcna.2022.08.001_bib84","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12879-021-06141-4","article-title":"Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis","volume":"21","author":"Ledesma","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.mcna.2022.08.001_bib85","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.tube.2020.102033","article-title":"Host transcriptional response to TB preventive therapy differentiates two sub-groups of IGRA-positive individuals","volume":"127","author":"Broderick","year":"2021","journal-title":"Tuberculosis (Edinb)"},{"issue":"9","key":"10.1016\/j.mcna.2022.08.001_bib86","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.mcna.2022.08.001_bib87","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2015.11.017","article-title":"Risk of Active Tuberculosis in the Five Years Following Infection . . . 15%?","volume":"149","author":"Trauer","year":"2016","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.mcna.2022.08.001_bib88","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41591-020-1076-0","article-title":"Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat Med"},{"issue":"10228","key":"10.1016\/j.mcna.2022.08.001_bib89","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","article-title":"The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis","volume":"395","author":"Martinez","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2022.08.001_bib90","first-page":"793","article-title":"A\u00a0follow-up study of tuberculosis incidence and general mortality in various occupational-social groups of the Danish population","volume":"24","author":"Horwitz","year":"1961","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.mcna.2022.08.001_bib91","first-page":"572","article-title":"Tuberculosis morbidity in the U.S. Navy: its distribution and decline","volume":"110","author":"Comstock","year":"1974","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.mcna.2022.08.001_bib92","first-page":"1","article-title":"Chapter 4: Diagnosis of Latent Tuberculosis Infection","author":"Pai","year":"2013","journal-title":"Can J Respir Crit Care Sleep Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712522000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712522000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:47:36Z","timestamp":1758419256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712522000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0025712522000943"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2022.08.001","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testing and Treating Mycobacterium tuberculosis Infection","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}